MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

A

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Search

REGENXBIO Inc

Closed

SectorHealthcare

10.55 8.88

Overview

Share price change

24h

Current

Min

9.68

Max

10.55

Key metrics

By Trading Economics

Income

-77M

-71M

Sales

-68M

21M

Profit margin

-331.809

Employees

353

EBITDA

-68M

-56M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+142.63% upside

Market Stats

By TradingEconomics

Market Cap

78M

498M

Previous open

1.67

Previous close

10.55

News Sentiment

By Acuity

86%

14%

354 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

REGENXBIO Inc Chart

Past performance is not a reliable indicator of future results.

Related News

22 Apr 2025, 09:30 UTC

Top News

Trump's FDA Sends a Bullish Signal to Biotech -- Heard on the Street -- WSJ

Peer Comparison

Price change

REGENXBIO Inc Forecast

Price Target

By TipRanks

142.63% upside

12 Months Forecast

Average 25.67 USD  142.63%

High 40 USD

Low 14 USD

Based on 9 Wall Street analysts offering 12 month price targets forREGENXBIO Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

9 ratings

8

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

6.99 / 7.92Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Bullish Evidence

Sentiment

By Acuity

354 / 371 Healthcare

News Sentiment

Very Strong Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About REGENXBIO Inc

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
help-icon Live chat